Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder
Phase of Trial: Phase IV
Latest Information Update: 23 May 2017
At a glance
- Drugs Darifenacin (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors Novartis
- 12 Jul 2007 Status changed from in progress to completed.
- 19 Nov 2005 New trial record.